Chemotherapy remains an essential element of personalized care for persons with lung cancers

Por Hellmann, M. D., Li, B. T., Chaft, J. E., Kris, M. G.
Publicado no Ann Oncol (2016)

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Por Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., Riely, G. J.
Publicado em 2014

Differences in survival of patients with recurrent versus de novo metastatic KRAS and EGFR mutant lung cancers

Por Yu, H. A., Sima, C. S., Hellmann, M. D., Naidoo, J., Busby, N., Rodriguez, K., Riely, G. J., Kris, M. G.
Publicado no Cancer (2015)

Clinical Characteristics and Course of 63 patients with BRAF Mutant Lung Cancers

Por Litvak, A.M., Paik, P.K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M.E., Ladanyi, M., Rudin, C. M., Kris, M. G., Riely, G. J.
Publicado no J Thorac Oncol (2014)

Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor

Por Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D., Lacouture, M.E.
Publicado no Eur J Cancer (2016)

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

Por Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., Merghoub, T., Rudin, C. M., Fish, S., Hellmann, M. D.
Publicado no Ann Oncol (2017)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Por Drilon, A., Bergagnini, I., Delasos, L., Sabari, J., Woo, K. M., Plodkowski, A., Wang, L., Hellmann, M. D., Joubert, P., Sima, C. S., Smith, R., Somwar, R., Rekhtman, N., Ladanyi, M., Riely, G. J., Kris, M. G.
Publicado no Ann Oncol (2016)

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Por Derosa, L, Hellmann, M D, Spaziano, M, Halpenny, D, Fidelle, M, Rizvi, H, Long, N, Plodkowski, A J, Arbour, K C, Chaft, J E, Rouche, J A, Zitvogel, L, Zalcman, G, Albiges, L, Escudier, B, Routy, B
Publicado no Ann Oncol (2018)

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Por Hui, R., Garon, E. B., Goldman, J. W., Leighl, N. B., Hellmann, M. D., Patnaik, A., Gandhi, L., Eder, J. P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G. M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N. A.
Publicado no Ann Oncol (2017)

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Por Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., Hellmann, M. D., Dong, D., Li, C., Mayawala, K., Freshwater, T., Ahamadi, M., Stone, J., Lubiniecki, G. M., Zhang, J., Im, E., De Alwis, D. P., Kondic, A. G., Fløtten, Ø.
Publicado no Ann Oncol (2016)

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Por Sabari, J K, Leonardi, G C, Shu, C A, Umeton, R, Montecalvo, J, Ni, A, Chen, R, Dienstag, J, Mrad, C, Bergagnini, I, Lai, W V, Offin, M, Arbour, K C, Plodkowski, A J, Halpenny, D F, Paik, P K, Li, B T, Riely, G J, Kris, M G, Rudin, C M, Sholl, L M, Nishino, M, Hellmann, M D, Rekhtman, N, Awad, M M, Drilon, A
Publicado no Ann Oncol (2018)

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Por Cottrell, T R, Thompson, E D, Forde, P M, Stein, J E, Duffield, A S, Anagnostou, V, Rekhtman, N, Anders, R A, Cuda, J D, Illei, P B, Gabrielson, E, Askin, F B, Niknafs, N, Smith, K N, Velez, M J, Sauter, J L, Isbell, J M, Jones, D R, Battafarano, R J, Yang, S C, Danilova, L, Wolchok, J D, Topalian, S L, Velculescu, V E, Pardoll, D M, Brahmer, J R, Hellmann, M D, Chaft, J E, Cimino-Mathews, A, Taube, J M
Publicado no Ann Oncol (2018)

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Por Forde, P.M., Chaft, J.E., Smith, K.N., Anagnostou, V., Cottrell, T.R., Hellmann, M.D., Zahurak, M., Yang, S.C., Jones, D.R., Broderick, S., Battafarano, R.J., Velez, M.J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K.A., Verde, F., Guo, H., Zhang, J., Caushi, J.X., Chan, H.Y., Sidhom, J.-W., Scharpf, R.B., White, J., Gabrielson, E., Wang, H., Rosner, G.L., Rusch, V., Wolchok, J.D., Merghoub, T., Taube, J.M., Velculescu, V.E., Topalian, S.L., Brahmer, J.R., Pardoll, D.M.
Publicado no N Engl J Med (2018)